Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Gothenburg, May 28, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on its proprietary commercial technology platform iTANK, today announces that it has entered into a Material Transfer Agreement (MTA) with University Hospital Tübingen in Germany. Under the agreement, the company's oncolytic virus candidates ELC-100 and ELC-201 will be included in tests aimed at developing a new type of companion diagnostic to predict the potential success of a novel neuroendocrine neoplasm (NEN) therapy, immuno-virotherapy.
Immuno-virotherapy (IV) represents an innovative treatment modality for neuroendocrine neoplasms (NENs). IV combines intratumoral administration of oncolytic viruses (OVs) with intravenous administration of an anti-PD1 immune checkpoint inhibitor. For IV to be effective, it is a strict prerequisite that NEN patients' tumor cells (i) are permissive to OV infection, (ii) support massive OV replication in the infected tumor cells, and (iii) that the OV infection leads to OV-induced destruction (oncolysis) of the NEN cells. If these three conditions are not met, the OV + anti-PD1 combination strategy will not succeed.
According to Elicera's MTA with University Hospital Tübingen, the hospital, under the leadership of Professor Ulrich M. Lauer and Dr. Linus Kloker, will receive access to ELC-100 and ELC-201 to conduct testing aimed at developing a new type of companion diagnostic. The purpose of this diagnostic is to predict the potential success of immuno-virotherapy before initiating treatment with this new combination for NEN. Tests will also be conducted on other oncolytic viruses, including the market-approved IMLYGIC™ (AMGEN).
"There is a clear scientific rationale for combining oncolytic viruses with anti-PD1 immune checkpoint inhibitors. Participating in this project gives us a valuable opportunity to contribute our oncolytic viruses while gathering important data on their activity in fresh tumor tissue. We see a strong health-economic value in developing methods to identify which patients are most likely to respond to treatment - something particularly relevant in a heterogeneous disease group like NEN. Our participation is not only a way to strengthen our own knowledge base, but also a contribution to accelerating the development of new and more precise therapies for this patient population", says Jamal El-Mosleh, CEO of Elicera Therapeutics.
"The advancement of precision medicine depends on effectively linking research progress with clinical needs. Identifying the right treatment for the right patient requires close collaboration between academia, healthcare, and the innovative life science industry. This project is a concrete example of how we can take important steps together toward more individualized and effective cancer care, where advanced diagnostics and targeted therapies go hand in hand", says Dr. and Professor Ulrich M. Lauer, University Hospital Tübingen.